SAN DIEGO--(BUSINESS WIRE)--

Cytori Therapeutics, Inc. (NASDAQ: CYTX) will present new preclinical data describing positive effects of Cytori Cell Therapy™ on a corneal wound healing model and in cutaneous scarring following burn injury. The data will be presented at the International Federation for Adipose Therapeutics (IFATS) in San Diego on November 17-20, 2016.

One presentation is titled “Adipose-Derived Regenerative Cells Promote Proliferation of Corneal Epithelial Cell And Corneal Wound Healing.” This presentation will focus on the effects of Cytori Cell Therapy on corneal wound healing using cell culture and corneal explant culture models. The cornea is particularly sensitive to injury following exposure to chemical agents and there is an unmet need for therapies capable of promoting corneal healing following accidental or terrorist-initiated exposure to chemical agents.

Another presentation is titled “Autologous Adipose Derived Regenerative Cell (ADRCs) Therapy For The Prevention And Treatment Of Hypertrophic Scars Using A Red Duroc Porcine Model,” which suggests the ability of Cytori’s DCCT-10 cell therapy to mitigate the development of hypertrophic scarring in a porcine model.

This research was funded by Cytori’s contract with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (HHSO100201200008C).

About Cytori Therapeutics, Inc.

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information, visit www.cytori.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends, and/or business prospects, which may affect our future operating results and financial position. Such statements, including statements regarding potential benefits of use of topical or intravenous administration of Cytori Cell Therapy in corneal wound and burn patients (including for wound healing and reduction of hypertrophic scarring), are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. These risks and uncertainties include preclinical, clinical and regulatory uncertainties, such as risks in the collection and results of preclinical data, risks that any proposed clinical trials regarding wound and scar healing are not approved or funded, risks that BARDA may lose the ability to keep funding Cytori’s clinical studies, or may elect to discontinue its funding of Cytori’s work, unfavorable results of any clinical studies or trials using Cytori Cell Therapy, final clinical outcomes, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, included in our annual and quarterly reports. There may be events in the future that we are unable to predict, or over which we have no control, and our business, financial condition, results of operations and prospects may change in the future. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless we have an obligation under U.S. Federal securities laws to do so.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161104005212/en/